GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,221.00
-91.00 (-6.94%)
Last updated: Feb 25, 2026, 3:00 PM KST
Market Cap104.03B -40.6%
Revenue (ttm)30.90B -18.6%
Net Income-51.36B
EPS-627.50
Shares Out85.20M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,556,296
Average Volume2,678,462
Open1,325.00
Previous Close1,312.00
Day's Range1,220.00 - 1,325.00
52-Week Range1,200.00 - 4,270.00
Beta0.72
RSI22.63
Earnings DateMar 18, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.

Financial Statements